Two major cancer informatics companies—Flatiron Health and Caris Life Sciences—have created a partnership to generate combined biological and clinical real-world evidence datasets that can be used to inform the development of immuno-oncology agents and targeted cancer therapeutics.
Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
